Drug Approval | June 28, 2024
Eugia SEZ’s injectable facility gets EIR from USFDA
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Application based on results from the TROPION-Breast01 Phase III trial
Subscribe To Our Newsletter & Stay Updated
